Rhumbline Advisers trimmed its holdings in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) by 28.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,703 shares of the medical equipment provider's stock after selling 5,549 shares during the period. Rhumbline Advisers owned approximately 0.11% of iRadimed worth $719,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the business. US Bancorp DE raised its holdings in iRadimed by 476.6% during the fourth quarter. US Bancorp DE now owns 617 shares of the medical equipment provider's stock worth $34,000 after purchasing an additional 510 shares in the last quarter. Huntington National Bank boosted its stake in iRadimed by 34.0% during the 4th quarter. Huntington National Bank now owns 1,993 shares of the medical equipment provider's stock valued at $110,000 after purchasing an additional 506 shares in the last quarter. State of Wyoming acquired a new position in shares of iRadimed during the 4th quarter valued at $149,000. Avantax Advisory Services Inc. bought a new stake in shares of iRadimed in the 4th quarter worth $217,000. Finally, Bessemer Group Inc. raised its stake in shares of iRadimed by 9.6% in the 4th quarter. Bessemer Group Inc. now owns 4,143 shares of the medical equipment provider's stock worth $228,000 after buying an additional 362 shares in the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Separately, Wall Street Zen raised iRadimed from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, May 6th.
Check Out Our Latest Stock Analysis on IRMD
iRadimed Price Performance
Shares of IRMD traded down $0.08 during mid-day trading on Wednesday, hitting $60.40. The company's stock had a trading volume of 54,387 shares, compared to its average volume of 43,668. The firm has a 50-day moving average price of $55.21 and a 200 day moving average price of $55.16. iRadimed Corporation has a fifty-two week low of $42.34 and a fifty-two week high of $63.29. The stock has a market capitalization of $768.29 million, a price-to-earnings ratio of 38.97 and a beta of 0.92.
iRadimed Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, May 30th. Shareholders of record on Tuesday, May 20th were given a $0.17 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $0.68 annualized dividend and a yield of 1.13%. iRadimed's dividend payout ratio (DPR) is 43.87%.
iRadimed Company Profile
(
Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Recommended Stories
Before you consider iRadimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRadimed wasn't on the list.
While iRadimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
